PA
FDMT icon

Perceptive Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Perceptive Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-375,256
Closed -$10.1M – 152
2021
Q3 		$10.1M Hold
375,256
– – 0.15% 100
2021
Q2 		$9.04M Sell
375,256
-69,622
-16% -$2.13M 0.12% 113
2021
Q1 		$19.3M Sell
444,878
-155,378
-26% -$6.88M 0.24% 80
2020
Q4 		$24.9M Buy
+600,256
New +$24.8M 0.27% 77

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's FDMT Position: Q4 2021 in Review

Perceptive Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q4 2021, closing a stake of 375,256 shares — an estimated $10.1M sold.

Perceptive Advisors first reported a position in FDMT in Q4 2020 and held it in 4 quarters. The position peaked at $24.9M in Q4 2020. 77 funds tracked by Wall St. Rank hold FDMT as of Q4 2021.

  • Perceptive Advisors reported no remaining 4D Molecular Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Perceptive Advisors sold 375,256 4D Molecular Therapeutics shares in Q4 2021, an estimated $10.1M.
  • Perceptive Advisors first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 4 quarters.
  • Perceptive Advisors's 4D Molecular Therapeutics position peaked at $24.9M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2021.

Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.